04 Sep, 2024 Poland - Life Sciences Monthly Brief, August 2024 By Andrzej Balicki, Ph.D. Jolanta Dabrowicz Przemysław Matuszewski Urszula Grębowska +1 more... Show less Download a copy of our July monthly briefing, which covers key updates and insights in the following areas: Medicinal products;Medical...
04 Sep, 2024 Anticorruption and anti-money laundering top the UAE’s enforcement agenda: Key takeaways for the Life Sciences Sector By Adam Vause Celia Johnson-Morgan Katie Edwards Governments around the world continue to place corporate crime at the top of their enforcement agendas, and the United Arab Emirates...
25 Oct, 2023 Artificial Intelligence and healthcare: the Italian DPA adopts a decalogue on GDPR compliance of national healthcare services using AI By Cristina Criscuoli The use of artificial intelligence (‘AI’) systems in the pharmaceutical and healthcare sectors is growing exponentially, with...
20 Sep, 2023 Sex bias, racial bias and AI – An ESG issue for the life sciences and healthcare sectors By Nicholas Tyacke Greg Bodulovic Alexandra de Zwart Alex Horder Jordan Davis +2 more... Show less It is increasingly important for organisations wishing to be good corporate citizens to have robust policies in place surrounding the...
16 May, 2023 The future of the assisted reproductive technology (ART): Modernising ART processes with AI By Nicholas Tyacke Greg Bodulovic Alexandra de Zwart Abi Ketheeswaran +1 more... Show less Assisted fertilisation processes involve striking the perfect balance between a range of complex factors – all of which play a critical...
28 Apr, 2023 The UK voluntary scheme for branded medicines pricing and access (VPAS): just what the doctor ordered, or a bitter pill to swallow? By Michael Stead Martha Pownall On the 1 April this year, amidst storm clouds gathering above the NHS in the form of staffing strikes, record waiting times and chronic...
10 Mar, 2023 Poland - Life Sciences monthly brief, February 2023 By Andrzej Balicki, Ph.D. Jolanta Dabrowicz Przemysław Matuszewski Urszula Grębowska +1 more... Show less Download a copy of our January monthly briefing, which covers key updates and insights in the following areas: Medicinal productsClinical...
09 Feb, 2023 Portugal: A transformation of the healthcare system may be under way By Mariana Ricardo Pharmacies have always played a relevant role in healthcare in Portugal, where pharmacists and pharmacy technicians traditionally share...
01 Feb, 2023 Working on the affordability of medicines: 2023 begins with an important message on excessive pricing - Portugal By Mariana Ricardo Early this year, the Portuguese Minister of Health stated the public expense with medicines in 2022 showed an increase of more than EUR...
20 Oct, 2022 The potential for unintended consequences in the Inflation Reduction Act By Jim Greenwood Alex Pinson Jamie Gregorian The Inflation Reduction Act (IRA) significantly impacts the US economic model for prescription drug innovation through the imposition of...
13 Jun, 2022 Summer of 2022; the dawn of the behemoth, Haleon plc By Robert Newman Think back almost four years to December 2018. A certain Donald Trump was POTUS, Theresa May survived a vote of no confidence (by a vote...
04 Apr, 2022 MHRA announce new scheme for monitoring good manufacturing and distributions practices in IAG cases By Taryn Jones Teresa Hitchcock The Medicines & Healthcare products Regulatory Agency (MHRA) has announced a new supervisory scheme as part of its process for monitoring...
16 Mar, 2022 UK ABPI calls for standardised international approach to university-industry collaborations By Richard Taylor Anna Wrench The Association of the British Pharmaceutical Industry (ABPI, the UK’s leading association for pharmaceutical companies), has published a...
18 Feb, 2022 Clinical Trial Regulations in the EU – how will the UK follow? By Kate Black The European Medicines Agency has confirmed that the new Clinical Trials Regulation is now in effect as of 31 January 2022. Please see...
08 Feb, 2022 An analysis of the effect of drug pricing provisions in the Build Back Better Act on pharmaceutical innovation By Kirsten Axelsen Having previously examined the impact of implementing international reference pricing in the United States, Charles River Associates (a...
17 Jan, 2022 Legislative initiative on off-label prescription By Vadim Barbu Off-label use of medication is currently not regulated in Romania. Rather, it is up to the doctors to decide on the off-label use of a...